BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. 2010

Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Department of Chemistry, School of Sciences, Islamic Azad University, Ahvaz Branch, Ahvaz, 61349-68875, Islamic Republic of Iran.

Selective PDE3 (phosphodiesterase 3) inhibitors improve cardiac contractility and may be used in congestive heart failure. However, their proarrhythmic potential is the most important side effect. In this work ten new synthetic compounds (3-[(4-methyl-2-oxo-1,2-dihydro-6-quinolinyl)oxy]methylbenzamide analogs: 4a-j) were designed, synthesized and tested for the inhibitory activity against human PDE3A and PDE3B. The strategy of the design was based on the structure of vesnarinone (a selective PDE3 inhibitor) and its docking analysis results. The synthetic compounds showed better PDE3 inhibitory activity in comparison with vesnarinone. Using docking analysis, a common binding model of each compound toward PDE3 was suggested. In the next step the potential cardiotonic activity of the best PDE3A inhibitors (4b, IC(50)=0.43+/-0.04microM) was evaluated by using the spontaneously beating atria model. In the experiment, atrium of reserpine-treated rat was isolated and the contractile and chronotropic effects of the synthetic compound were assessed. That was carried out in comparison with vesnarinone. The best pharmacological profile was obtained for the compound 4b, which displayed selectivity for increasing the force of contraction (46+/-3% change over the control) rather than the frequency rate (16+/-4% change over the control) at 100microM.

UI MeSH Term Description Entries
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D011804 Quinolines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001549 Benzamides BENZOIC ACID amides.
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives as inotropic agents.
August 2009, Journal of enzyme inhibition and medicinal chemistry,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
January 2015, Anti-cancer agents in medicinal chemistry,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
January 2017, European journal of medicinal chemistry,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and biological evaluation of novel dihydroquinolin-4(1H)-one derivatives as novel tubulin polymerization inhibitors.
December 2023, European journal of medicinal chemistry,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.
October 2020, European journal of medicinal chemistry,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors.
March 2021, European journal of medicinal chemistry,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and biological evaluation of 4-(alkyloxy)-6-methyl-2H-pyran-2-one derivatives as quorum sensing inhibitors.
August 2015, Bioorganic & medicinal chemistry letters,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.
May 2018, European journal of medicinal chemistry,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one derivatives as novel FXIa inhibitors.
January 2024, Bioorganic & medicinal chemistry letters,
Mohsen Nikpour, and Hamid Sadeghian, and Mohammad Reza Saberi, and Reza Shafiee Nick, and Seyed Mohammad Seyedi, and Azar Hosseini, and Heydar Parsaee, and Alireza Taghian Dasht Bozorg
Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.
January 2016, Drug design, development and therapy,
Copied contents to your clipboard!